Keyword: cancer

News

ChemoCentryx Trial of CCR2 Inhibitor for Pancreatic Cancer

21.04.2015 - ChemoCentryx, Inc, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, has begun enrolling patients with non-resectable...

News

Residues of Glyphosate Found in Food and Body Fluids

17.04.2015 - Private labs in the US are said to have found significant residues of the glyphosate weed-killer, marketed by agrochemicals giant Monsanto as Roundup, in samples of honey, soy...

News

Merck Serono and Illumina in Oncology Diagnostics Pact

11.03.2015 - Merck Serono, the biopharmaceutical business of Germany's Merck KGaA, and US biotechnology company Illumina, based at San Diego, California, plan to collaborate on expanding the...

News

DuPont Wins Whistleblower Case Over Leak

01.02.2015 - A jury in Baton Rouge, Louisiana has issued a verdict favouring DuPont in a whistleblower suit alleging leaks of cancer-causing gas at the company's sulfuric acid plant in Burnside...

News

Cancer Researcher Says Fracking Chemicals Are Carcinogens

23.01.2015 - Chemicals "known to be carcinogens," such as benzene and formaldehyde, being used in hydraulic fracturing (fracking) for shale gas in South Africa's Karoo basin, could lead to an...

News

Lucentis and Avastin Said to Have Similar Side Effects

16.09.2014 - Roche's cancer drug Avastin as a cheaper treatment for wet age-related macular degeneration (wAMD), a leading cause of blindness in the elderly, does not appear to increase deaths...

News

Google and AbbVie Partner on R&D for Age-related Illnesses

12.09.2014 - Calico, an investment firm founded by Google to fund projects aimed at delaying the human aging process, is partnering with US drugmaker AbbVie to develop therapies for age-related...

News

Merck KGaA and MorphoSys in Joint Antibody R&D

13.06.2014 - Germany's Merck and compatriot biotech firm MorphoSys have agreed to cooperate on discovering and developing therapeutic antibodies against undisclosed immune checkpoints, that is...